Abstract Aims In May 2016, a new version of the European Society of Cardiology (ESC)
Guidelines for the management of heart failure (HF) was released. The aim of this study was …

The extent and impact of under-prescribing of evidence-based pharmacological therapies
among heart failure patients with reduced ejection fraction (HFREF) in contemporary …

Background Renin-angiotensin system inhibitors and beta-blockers are the initial treatment
of choice for heart failure with reduced ejection fraction (HFrEF), whereas sacubitril/valsartan …

Background Guideline recommendations for the treatment of heart failure with mildly
reduced ejection fraction (HFmrEF) derive from small subgroups in post-hoc analyses of …

Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696)
reduced cardiovascular morbidity and mortality compared with enalapril in patients with …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Aims In symptomatic patients with heart failure and reduced ejection fraction (HFrEF), recent
international guidelines recommend initiating four major therapeutic classes rather than …

Aims Failure to prescribe key medicines at evidence‐based doses is associated with
increased mortality and hospitalization for patients with Heart Failure with reduced Ejection …

Aims The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is
likely to change the approach to the management of patients with chronic heart failure with …

Background The US Food and Drug Administration approved sacubitril/valsartan for patients
with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the …